Get the Stockscreener App
10.30
10.43%
-1.20
Exicure Inc stock is traded at $10.30, with a volume of 13,640.
It is down -10.43% in the last 24 hours and up +11.83% over the past month.
Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.
See More
Previous Close:
$11.50
Open:
$11.9
24h Volume:
13,640
Relative Volume:
0.02
Market Cap:
$31.94M
Revenue:
$28.83M
Net Income/Loss:
$-13.34M
P/E Ratio:
-6.7763
EPS:
-1.52
Net Cash Flow:
$-7.49M
1W Performance:
-8.28%
1M Performance:
+11.83%
6M Performance:
+303.13%
1Y Performance:
+203.70%
1-Day Range:
$10.16
$11.90
1-Week Range:
$10.00
$12.00
52-Week Range:
$1.44
$36.00
Exicure Inc Stock (XCUR) Company Profile
Name
Exicure Inc
Sector
Industry
Phone
847-673-1700
Address
2430 N. HALSTED ST., CHICAGO, IL
Compare XCUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
PSNYW
Polestar Automotive Holding Uk
|
0.1978 | 409.20M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.70 | 372.90M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
0.4356 | 278.60M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.26 | 96.03M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
4.00 | 52.42M | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-18-20 | Initiated | BMO Capital Markets | Outperform |
| Nov-20-19 | Initiated | Guggenheim | Buy |
Exicure Inc Stock (XCUR) Latest News
How the (XCUR) price action is used to our Advantage - Stock Traders Daily
Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 17.3% in January - Defense World
Hitron Systems Inc. announced that it expects to receive KRW 30 billion in funding -September 05, 2024 - Marketscreener.com
Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes - MSN
Exicure Inc (XCUR) requires closer examination - US Post News
Exicure signs purchase agreement with GPCR Therapeutics - MSN
Exicure, back from brink and under new management, buys GPCR's US unit and clinical-stage drug - Fierce Biotech
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. - BioSpace
CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. - Yahoo Finance
Exicure announces purchase agreement with GPCR Therapeutics - TipRanks
Exicure Acquires GPCR Therapeutics USA, Signs Major Licensing Deal for Drug Development - StockTitan
Exicure, Inc. (NASDAQ:XCUR) Sees Significant Decrease in Short Interest - Defense World
When (XCUR) Moves Investors should Listen - Stock Traders Daily
Exicure appoints new audit committee members By Investing.com - Investing.com Nigeria
Exicure Secures $8.7 Million in Stock Purchase Deal - MSN
Exicure appoints new audit committee members - Investing.com
Exicure, Inc. (NASDAQ:XCUR) Short Interest Update - Defense World
Exicure Stock Surges On Blood Cancer Portfolio Acquisition Plans, Regaining Nasdaq Compliance: Retail Exuberant - MSN
A Northwestern-born startup has new ownership — and a new focus - Crain's Chicago Business
Exicure Stock Surges On Blood Cancer Portfolio Acquisition Plans, Regaining Nasdaq Compliance: Retail Exuberan - Asianet Newsable
Exicure joins hands with GPCR Therapeutics for growth in biotech (NASDAQ:XCUR) - Seeking Alpha
Exicure signs MOU with GPCR Therapeutics - TipRanks
Exicure (XCUR) to Acquire GPCR USA, Gains Phase 2 Cancer Drug Pipeline with $2B Market Potential - StockTitan
Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech - Yahoo Finance
CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes - Business Wire
Exicure Names Andy Yoo as President, CEO - MarketWatch
Exicure Shareholders Approve Major HiTron Equity Financing - TipRanks
Exicure, Inc. Appoints Andy Yoo as Chief Executive Officer - Marketscreener.com
Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive - EIN News
Exicure Secures $12M Strategic Investment as HiTron Systems Takes Majority Stake - StockTitan
Exicure (NASDAQ:XCUR) Unaudited Proforma Consolidated Balance Sheets Show Growth - Defense World
Exicure boosts equity, eyes Nasdaq compliance - Investing.com
Exicure boosts equity, eyes Nasdaq compliance By Investing.com - Investing.com Australia
Stock market news: Exicure -34.53%, Senti Biosciences -23.70% among biggest losers in early trading - Business Upturn
Learn to Evaluate (XCUR) using the Charts - Stock Traders Daily
Short Interest in Exicure, Inc. (NASDAQ:XCUR) Decreases By 47.9% - Defense World
Exicure Stock Soars to 52-Week High, Hits $32.75 By Investing.com - Investing.com South Africa
Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 47.9% in November - MarketBeat
Exicure Stock Soars to 52-Week High, Hits $32.75 - Investing.com India
How Is The Market Feeling About Exicure? - Benzinga
Exicure appoints new directors and receives $1.3 million funding By Investing.com - Investing.com South Africa
Exicure appoints new directors and receives $1.3 million funding - Investing.com
Exicure, Inc. (XCUR): Strategic Equity Financing and Operational Restructuring Signal a New Beginning - BP Journal
Exicure Inc Stock (XCUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Exicure Inc Stock (XCUR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DGP Co., Ltd. | 10% Owner |
Feb 29 '24 |
Sale |
1.32 |
3,400,000 |
4,488,000 |
0 |
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):